| 000 | 05799cam a2200817 i 4500 | ||
|---|---|---|---|
| 001 | ocn857664391 | ||
| 003 | OCoLC | ||
| 005 | 20230823095259.0 | ||
| 006 | m o d | ||
| 007 | cr ||||||||||| | ||
| 008 | 130903s2014 nju ob 001 0 eng | ||
| 010 | _a 2013035811 | ||
| 040 |
_aDLC _beng _erda _cDLC _dYDX _dEBLCP _dN$T _dIDEBK _dDG1 _dYDXCP _dE7B _dCUI _dCUS _dCDX _dCOO _dRECBK _dOCLCF _dSTF _dOCLCQ _dDEBBG _dLOA |
||
| 019 |
_a905856541 _a929527164 _a960199933 _a961650872 _a962632779 |
||
| 020 | _a9781118778128 (ePub) | ||
| 020 | _a111877812X (ePub) | ||
| 020 | _a9781118778159 (Adobe PDF) | ||
| 020 | _a1118778154 (Adobe PDF) | ||
| 020 | _z9780470917374 (cloth) | ||
| 020 | _a9781118778166 | ||
| 020 | _a1118778162 | ||
| 020 | _a0470917377 | ||
| 020 | _a9780470917374 | ||
| 020 | _a9781306571784 | ||
| 020 | _a1306571782 | ||
| 029 | 1 |
_aCHVBK _b325941823 |
|
| 029 | 1 |
_aCHBIS _b010259524 |
|
| 029 | 1 |
_aNZ1 _b15922666 |
|
| 029 | 1 |
_aNZ1 _b16097921 |
|
| 029 | 1 |
_aDEBBG _bBV042792988 |
|
| 029 | 1 |
_aDEBBG _bBV043396198 |
|
| 035 |
_a(OCoLC)857664391 _z(OCoLC)905856541 _z(OCoLC)929527164 _z(OCoLC)960199933 _z(OCoLC)961650872 _z(OCoLC)962632779 |
||
| 042 | _apcc | ||
| 050 | 0 | 0 | _aRM301.25 |
| 060 | 1 | 0 | _aQV 745 |
| 072 | 7 |
_aMED _x071000 _2bisacsh |
|
| 082 | 0 | 0 |
_a615.1/9 _223 |
| 049 | _aMAIN | ||
| 245 | 0 | 0 |
_aCollaborative innovation in drug discovery : _bstrategies for public and private partnerships / _cedited by Dr. Rathnam Chaguturu. |
| 264 | 1 |
_aHoboken, New Jersey : _bJohn Wiley & Sons Inc., _c[2014] |
|
| 300 | _a1 online resource. | ||
| 336 |
_atext _2rdacontent |
||
| 337 |
_acomputer _2rdamedia |
||
| 338 |
_aonline resource _2rdacarrier |
||
| 490 | 1 | _aWiley series on technologies for the pharmaceutical industry | |
| 504 | _aIncludes bibliographical references and index. | ||
| 588 | _aDescription based on print version record and CIP data provided by publisher. | ||
| 505 | 0 | _aTable of Contents; Wiley Series on Technologies for the Pharmaceutical Industry; Title page; Copyright page; Dedication; Collaborative Drug Discovery Ethos; Foreword; Preface; About the Book; About the Editor; Contributors; Part I: Perspectives on Collaborative Innovation; 1: Productive Relationships in Research and Development between Government, Industry, and Universities; Universities, Government, and Industry: Historical Beginnings in Prussia; Refinement and Broad Adoption: the United States; General Principles for Success; Notes; 2: Divided We Fall; Challenges; Collaboration Models | |
| 505 | 8 | _aExamples of Successful Biomedical CollaborationsPrinciples of Collaboration; Governance, Administration, and Autonomy; Human Factors; Conclusion; References; 3: Innovation: Open Source and Nonprofit Models in Drug Discovery; Why Do People Innovate?; How Do We Encourage Innovation?; Why Is Innovation Important?; Warnings Regarding Innovation in Drug Discovery; Open Source Models; Nonprofit Models; Recommendations; References; 4: The Changing Face of Innovation in Drug Discovery; Introduction; Core Objectives of the Drug Discovery Process | |
| 505 | 8 | _aMajor Innovations in Technology Have Advanced Drug DiscoveryAn Important Trend: Academic and Pharmaceutical Organizations Are Collaborating in Support of Drug Discovery; Future Perspectives: Where Is Innovation Leading?; References; 5: Current Trends in Collaborative Drug Discovery and Strategies to De-Risk Precompetitive Initiatives; Pharmaceutical Industry's Perspective; Academia's Perspective; Open (Collaborative) Innovation: A New Business Model; Drug Discovery through Collaborations; Drug Discovery through Consortia; Drug Discovery through Repurposing Strategies | |
| 505 | 8 | _aProbe Discovery in Public DomainEffective Management of Academia-Pharma Collaborations; Concluding Remarks; References; Notes; 6: A Perspective on the Evolution of Collaborative Drug Discovery and Future Challenges; Evolution of Collaborative Drug Discovery; Challenges for Collaborative Drug Discovery; Conclusion; References; Part II: Governmental Initiatives Accelerate Precompetitive Collaboration; 7: The Value of University-Industry Partnerships; Guiding Principles for University-Industry Collaborations; The Johnson Continuum; Role of Cocreation: Companies, Government, and Universities | |
| 505 | 8 | _aFunding for Collaborations with AcademiaNew Initiatives to Transform University-Industry Collaborations; Issues Affecting University-Industry Collaborations; Differences between Large- and Small-/Medium-Sized Companies; Large Companies Share Certain Characteristics; Small- and Medium-Sized Enterprises (SMEs) Offer a Contrasting Perspective; The National Academies' University-Industry Demonstration Partnership; Strategies for Building High-Value, High Return U-I Partnerships; Conclusion; Note on this Chapter; Note; References | |
| 650 | 2 | _aDrug Discovery. | |
| 650 | 2 | _aPublic-Private Sector Partnerships. | |
| 650 | 7 |
_aMEDICAL _xPharmacology. _2bisacsh |
|
| 650 | 7 |
_aDrug development. _2fast _0(OCoLC)fst00898670 |
|
| 650 | 7 |
_aPublic-private sector cooperation. _2fast _0(OCoLC)fst01083445 |
|
| 650 | 0 | _aDrug Discovery. | |
| 650 | 0 | _aPublic-Private Sector Partnerships. | |
| 650 | 0 | _aDrug development. | |
| 650 | 0 | _aPublic-private sector cooperation. | |
| 650 | 4 | _aPublic-Private Sector Partnerships. | |
| 655 | 4 | _aElectronic books. | |
| 655 | 0 | _aElectronic books. | |
| 700 | 1 |
_aChaguturu, Rathnam, _eeditor of compilation. |
|
| 776 | 0 | 8 |
_iPrint version: _tCollaborative innovation in drug discovery _dHoboken, New Jersey : John Wiley & Sons Inc., [2014] _z9780470917374 _w(DLC) 2013035525 |
| 830 | 0 | _aWiley series on technologies for the pharmaceutical industry. | |
| 856 | 4 | 0 |
_uhttp://dx.doi.org/10.1002/9781118778166 _zWiley Online Library |
| 994 |
_a92 _bDG1 |
||
| 999 |
_c20809 _d20768 |
||
| 526 | _bgm | ||